Please assess the completion status of the following clinical trial:

Trial Title: TAP Block Using Liposomal Bupivacaine for Post-cesarean Delivery Analgesia- Walking Towards Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients between the ages of 18 and 45 presenting for cesarean delivery~2. ASA-1, ASA-2, ASA-3~3. No allergy to morphine~4. No allergy to bupivacaine~5. Patients with BMI \> 45 will be excluded~6. No history of anxiety~7. No recent or chronic opioid use~Exclusion Criteria:~1. Need for Magnesium sulfate therapy~2. Neonatal admission to neonatal intensive care unit~3. Need for additional surgery other than cesarean delivery +/- bilateral tubal ligation (e.g. hysterectomy, cystotomy)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Control group (Bupivacaine) (Type: ACTIVE_COMPARATOR): Patient will receive intrathecal morphine and TAP block with plain bupivacaine.
- Liposomal Bupivacaine (Type: EXPERIMENTAL): Patient will receive intrathecal morphine + TAP block with Liposomal bupivacaine and bupivacaine 0.25%
- Bupivacaine + dexamethasone and methylprednisolone (Type: ACTIVE_COMPARATOR): Patient will receive intrathecal morphine + TAP block with only bupivacaine.

Based on this trial design, predict the completion outcome and termination type (if applicable).